Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate
A. J. M. Schreurs, H. L. M. van Helmond, J. H. E. Schijen, L. P. M. Greefhorst, P. G. H. Mulder (Hertogenbosch, Roosendaal, Tilburg, Hengelo, Rotterdam, The Netherlands)
Source: Annual Congress 2003 - Similarities and differences between β-2 agonists
Session: Similarities and differences between β-2 agonists
Session type: Thematic Poster Session
Number: 1855
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. J. M. Schreurs, H. L. M. van Helmond, J. H. E. Schijen, L. P. M. Greefhorst, P. G. H. Mulder (Hertogenbosch, Roosendaal, Tilburg, Hengelo, Rotterdam, The Netherlands). Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate. Eur Respir J 2003; 22: Suppl. 45, 1855
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001
Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Characterization of asthma exacerbations by Arg16Gly genotype in subjects with asthma receiving salmeterol alone or with fluticasone propionate Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 458s Year: 2007
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Does fluticasone or montelukast reduce the risk of recurency of wheezing bronchitis comparing to no intervention in children under the age of 3 Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Survival in COPD patients after regular use of fluticasone propionate and salmeterol Source: Eur Respir J 2003; 21: 559-560 Year: 2003
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007